Jazz Pharmaceuticals’ (JAZZ) Neutral Rating Reaffirmed at Mizuho

Share on StockTwits

Mizuho reiterated their neutral rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report released on Monday morning, The Fly reports. Mizuho currently has a $173.00 target price on the specialty pharmaceutical company’s stock.

Other equities analysts also recently issued reports about the stock. Citigroup increased their price objective on shares of Jazz Pharmaceuticals from $162.00 to $205.00 and gave the company a buy rating in a research note on Tuesday, July 10th. Wells Fargo & Co reiterated a buy rating on shares of Jazz Pharmaceuticals in a research note on Sunday, July 8th. BidaskClub cut shares of Jazz Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Thursday, June 28th. B. Riley increased their target price on shares of Jazz Pharmaceuticals from $211.00 to $219.00 and gave the company a buy rating in a research report on Tuesday, June 26th. Finally, Cantor Fitzgerald set a $203.00 target price on shares of Jazz Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, August 7th. Two analysts have rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. Jazz Pharmaceuticals has a consensus rating of Buy and a consensus target price of $193.32.

NASDAQ JAZZ opened at $156.00 on Monday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.62 and a current ratio of 3.76. Jazz Pharmaceuticals has a 52-week low of $128.58 and a 52-week high of $184.00. The company has a market cap of $10.16 billion, a PE ratio of 16.46, a price-to-earnings-growth ratio of 0.92 and a beta of 1.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.23 by $0.26. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%. The firm had revenue of $500.48 million for the quarter, compared to the consensus estimate of $469.85 million. On average, equities analysts predict that Jazz Pharmaceuticals will post 11.7 earnings per share for the current year.

In related news, SVP Paul Treacy sold 1,309 shares of the stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $176.61, for a total transaction of $231,182.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Matthew P. Young sold 700 shares of the firm’s stock in a transaction on Monday, October 15th. The stock was sold at an average price of $158.08, for a total transaction of $110,656.00. Following the completion of the transaction, the chief financial officer now directly owns 32,768 shares of the company’s stock, valued at approximately $5,179,965.44. The disclosure for this sale can be found here. Insiders have sold 34,978 shares of company stock valued at $6,030,128 in the last three months. 3.90% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Summit Trail Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 8,591.5% in the first quarter. Summit Trail Advisors LLC now owns 102,125 shares of the specialty pharmaceutical company’s stock worth $102,000 after buying an additional 100,950 shares during the last quarter. Financial Gravity Wealth Inc. purchased a new position in shares of Jazz Pharmaceuticals in the first quarter worth $192,000. Tiverton Asset Management LLC purchased a new position in shares of Jazz Pharmaceuticals in the second quarter worth $198,000. Moloney Securities Asset Management LLC purchased a new position in shares of Jazz Pharmaceuticals in the second quarter worth $204,000. Finally, FDx Advisors Inc. purchased a new position in shares of Jazz Pharmaceuticals in the second quarter worth $244,000. 92.52% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Further Reading: Insider Trading

The Fly

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply